Re: [MOL] Fatigue/Reply to Laurie [01265] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Re: [MOL] Fatigue/Reply to Laurie



There is a drug called phenergan-antionousea that aides in keeping patients
eating.  Ensure as previously noted to you is also excellent.  How is your
mother's blood count?  Treatment for cancer causes extreme fatigue for many
.  If she is running anemic this would add to the normal fatigue.  Wishing
you the very best, warmly, lillian


We invite you to take a look at our Album.
www.angelfire.com/sc/molangels/index.html

  ( Very informational, good tips, Molers pictures, art work and much
more....

----- Original Message -----
From: "Laurie Marshall" <inposse1@hotmail.com>
To: <mol-cancer@lists.meds.com>
Sent: Sunday, July 23, 2000 9:44 AM
Subject: [MOL] Fatigue


>
> My mother has gone through the gauntlet with breast cancer;  the
operation,
> the chemo and she just finished her radiation treatments barely two weeks
> ago.  She's 66 and very petite, about 4'9" and around 101lbs.
>
> My question (from her) is this:  should she be as tired as she is?  She
> wakes up and about two hours later is ready for a nap.  The naps seem to
> help for a while, but she doesn't seem to be picking up at all.
>
> She also is having a problem with not eating, either due to an upset
stomach
> or simply because she doesn't want food.  If she forces herself to eat, it
> just goes straight through her.  Therefore, she is not gaining any weight.
> Actually, she had lost 3lbs, which brought her down to 101.
>
> She has told all the Drs. she's dealing with how tired she is and they all
> say it's "normal" and will last for "serveral" weeks.  Exactly what is
> several weeks?  Personally, I think she's worse now (both physically and
> mentally) than she was when she was going through everything.
>
> Can anyone help me out here?  I'm at my wits end on what to do to try and
> help her!
>
> Thanks!
>
> Laurie
>
> >From: "Lillian" <firefly@islc.net>
> >Reply-To: mol-cancer@lists.meds.com
> >To: "MOL" <mol-cancer@lists.meds.com>
> >Subject: [MOL] Some really good info. for most cancers....
> >Date: Sat, 22 Jul 2000 23:00:09 -0700
> >
> >
> > > | HEMATOLOGY-ONCOLOGY TREATMENT UPDATES - MONOCLONAL ANTIBODIES IN THE
> > > | TREATMENT OF CANCER
> > > | An update on the clinical benefits and therapeutic indications of
> > > | monoclonal antibodies currently used for routine or experimental
> >treatment
> > > | of patients with non-Hodgkin's lymphoma and breast cancer.
> > > | Hematology-Oncology Treatment Updates - (C) 2000 Medscape, Inc.
> > > | http://oncology.medscape.com/24773.rhtml
> > > | <a href="http://oncology.medscape.com/24773.rhtml">Read it Here</a>
> > > |
> > > | CANCER RISK IN PERSONS WITH HIV/AIDS IN THE ERA OF COMBINATION
> > > | ANTIRETROVIRAL THERAPY
> > > | Which types of cancer occur at increased rates in patients with HIV
> >and
> > > AIDS?
> > > | The AIDS Reader 10(6):341-346, 2000
> > > | http://oncology.medscape.com/24775.rhtml
> > > | <a href="http://oncology.medscape.com/24775.rhtml">Read it Here</a>
> > > |
> > > | GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: ASSOCIATION WITH
A
> >NEW
> > > | HELICOBACTER SPECIES
> > > | Epidemiologic and clinical investigations have established a
possible
> >link
> > > | between primary gastric mucosa-associated lymphoid tissue (MALT)
> >lymphoma
> > > | and chronic H. pylori infection.
> > > | Copyright (C) 1998, 1999, 2000 The McGraw-Hill Companies.
> > > | http://oncology.medscape.com/24618.rhtml
> > > | <a href="http://oncology.medscape.com/24618.rhtml">Read it Here</a>
> > > |
> > > | ASK THE EXPERTS - THE BEST TREATMENT FOR A T4 TRANSITIONAL BLADDER
> >CANCER?
> > > | What is the best therapeutic approach for transitional bladder
cancer
> >with
> > > | invasion of the rectum without evidence of metastatic disease in a
> > > | previously healthy 61-year-old male?
> > > | http://oncology.medscape.com/24703.rhtml
> > > | <a href="http://oncology.medscape.com/24703.rhtml">Read it Here</a>
> > > |
> > > | ASK THE EXPERTS - SURGERY OR CHEMOTHERAPY FOR A T3 LARYNGEAL CANCER?
> > > | In stage T3N1M0 squamous cell carcinoma of the larynx, is the
initial
> >use
> > > | of radiotherapy and chemotherapy -- with the provision to reconsider
> > > | surgery if the trial fails -- actually used and recommended?
> > > | http://oncology.medscape.com/24827.rhtml
> > > | <a href="http://oncology.medscape.com/24827.rhtml">Read it Here</a>
> > > |
> > > | GUEST EDITORIAL - THYROID CANCER IN THE NEW MILLENNIUM
> > > | The aftermath of the nuclear disaster at Chernobyl sensitized a
large
> > > | proportion of the general public about not only the importance of
> >thyroid
> > > | cancer as a disease, but also the need to minimize radiation
exposure
> >of
> > > | children as a preventive measure.
> > > | Cancer Control; JMCC 7(3):209-210, 2000.
> > > | http://oncology.medscape.com/24560.rhtml
> > > | <a href="http://oncology.medscape.com/24560.rhtml">Read it Here</a>
> > > |
> > > | NEUROIMAGING CASE CHALLENGE - A 42-YEAR-OLD WOMAN WITH SEIZURES AND
> >MENTAL
> > > | STATUS CHANGE
> > > | What's your diagnosis?
> > > | Medscape Neurology, 2000
> > > | http://oncology.medscape.com/24724.rhtml
> > > | <a href="http://oncology.medscape.com/24724.rhtml">Read it Here</a>
> > > |
> > > |
> >_______________________________________________________________________
> > > | ___________________________________ NEWS
> >______________________________
> > > |
> > > | ATOMIC BOMB SURVIVORS DO NOT LIVE LONGER THAN UNEXPOSED PEERS
> > > | Japanese survivors of the atomic bomb have their life expectancy
> >reduced
> > > by
> > > | an average of about 4 months, which does not support claims that
> >survivors
> > > | exposed to low levels of radiation live longer than comparable
> >unexposed
> > > | individuals.
> > > | http://oncology.medscape.com/24797.rhtml
> > > | <a href="http://oncology.medscape.com/24797.rhtml">Read it Here</a>
> > > |
> > > | COLONOSCOPY FAVORED FOR COLORECTAL CANCER SCREENING IN ASYMPTOMATIC
> >ADULTS
> > > | Colonoscopy should be used instead of sigmoidoscopy in screening for
> > > | colorectal cancer, according to two reports in the July 20th issue
of
> >the
> > > | New England Journal of Medicine.
> > > | http://oncology.medscape.com/24725.rhtml
> > > | <a href="http://oncology.medscape.com/24725.rhtml">Read it Here</a>
> > > |
> > > | TESTICULAR CANCER TREATMENT: SURVIVAL ADVANTAGE OUTWEIGHS RISK OF
> >LEUKEMIA
> > > | Modern radiation and chemotherapy regimens for testicular cancer are
> > > | associated with only a small excess risk of leukemia, which is far
> > > | outweighed by the survival advantage that treatment confers,
according
> >to
> > > a
> > > | multinational team of researchers.
> > > | http://oncology.medscape.com/24652.rhtml
> > > | <a href="http://oncology.medscape.com/24652.rhtml">Read it Here</a>
> > > |
> > > | COGNITIVE FUNCTION DECLINES IN BREAST CANCER PATIENTS UNDERGOING
> > > CHEMOTHERAPY
> > > | Women undergoing chemotherapy for breast cancer have significantly
> >reduced
> > > | cognitive function compared with healthy controls, according to a
team
> >of
> > > | Canadian researchers.
> > > | http://oncology.medscape.com/24527.rhtml
> > > | <a href="http://oncology.medscape.com/24527.rhtml">Read it Here</a>
> > > |
> > > | SATISFACTION HIGH AFTER PROPHYLACTIC BILATERAL MASTECTOMY
> > > | Most women are satisfied after bilateral prophylactic mastectomy and
> > > report
> > > | much less concern about developing breast cancer, according to
> >researchers
> > > | at the Mayo Foundation and Mayo Clinic, in Rochester, Minnesota.
> > > | http://oncology.medscape.com/24653.rhtml
> > > | <a href="http://oncology.medscape.com/24653.rhtml">Read it Here</a>
> > > |
> > > | SURVIVAL SIMILAR AFTER MASTECTOMY, BREAST-CONSERVING THERAPY FOR
STAGE
> >II
> > > | TUMORS
> > > | Breast-conserving therapy and radical mastectomy give similar
survival
> > > | rates in women with breast tumors larger than 2 cm, according to a
> >report
> > > | in the July 19th issue of the Journal of the National Cancer
> >Institute.
> > > | http://oncology.medscape.com/24658.rhtml
> > > | <a href="http://oncology.medscape.com/24658.rhtml">Read it Here</a>
> > > |
> > > | PATIENTS WITH SMALL BREAST CANCERS SHOULD HAVE AXILLA INVESTIGATED
FOR
> > > | METASTASIS
> > > | Increasing tumor size, poor histologic grade, and younger age are
> > > | significant predictors of axillary lymph node metastasis (ALNM) in
> > > patients
> > > | with invasive breast cancers 1 cm or less.
> > > | http://oncology.medscape.com/24734.rhtml
> > > | <a href="http://oncology.medscape.com/24734.rhtml">Read it Here</a>
> > > |
> > > | STEM CELL TRANSPLANT MAY BE BEST CHOICE FOR SELECTED METASTATIC
BREAST
> > > CANCERS
> > > | High-dose chemotherapy followed by hematopoietic stem cell
> >transplantation
> > > | has been found to be no more effective than standard therapy for
most
> > > | breast cancers, but this aggressive regimen may still be the best
> >approach
> > > | in selected patients, according to Dr. Roy B. Jones of the
University
> >of
> > > | Colorado Cancer Center in Denver.
> > > | http://oncology.medscape.com/24664.rhtml
> > > | <a href="http://oncology.medscape.com/24664.rhtml">Read it Here</a>
> > > |
> > > | MAMMOGRAPHY MAY IDENTIFY WOMEN AT INCREASED RISK FOR CARDIOVASCULAR
> > > DISEASE
> > > | Breast artery calcium (BAC) seen on mammography is associated with
> > > | increased risk of atherosclerotic cardiovascular disease, according
to
> > > | Israeli researchers.
> > > | http://oncology.medscape.com/24727.rhtml
> > > | <a href="http://oncology.medscape.com/24727.rhtml">Read it Here</a>
> > > |
> > > | GLANDULAR ATYPIA ON PAP TESTING WARRANTS AGGRESSIVE MANAGEMENT
> > > | The results of a community study carried out by US-based researchers
> > > | indicate that nearly half of patients with Pap smears classified as
> > > | containing atypical glandular cells of undetermined significance
> >(AGUS)
> > > had
> > > | not undergone subsequent tissue biopsy.
> > > | http://oncology.medscape.com/24726.rhtml
> > > | <a href="http://oncology.medscape.com/24726.rhtml">Read it Here</a>
> > > |
> > > | MOST MELANOMA PATIENTS DETECT THEIR OWN CANCER
> > > | More than half of melanoma patients detect their own cancers, with a
> > > | minority of cases detected by a physician.
> > > | http://oncology.medscape.com/24528.rhtml
> > > | <a href="http://oncology.medscape.com/24528.rhtml">Read it Here</a>
> > > |
> > > | GENETICALLY MODIFIED TUMOR VACCINE SHOWS EFFECT IN LATE-STAGE
MELANOMA
> > > | Preliminary results show that a genetically modified tumor vaccine
can
> > > | produce responses in some patients with late-stage melanoma.
> > > | http://oncology.medscape.com/24668.rhtml
> > > | <a href="http://oncology.medscape.com/24668.rhtml">Read it Here</a>
> > > |
> > > | SKIN CANCER SURVEILLANCE ADVISED FOR KIDNEY TRANSPLANT RECIPIENTS
> > > | Strategies are needed to reduce the incidence of nonmelanoma skin
> >cancers
> > > | among renal transplant recipients, according to British researchers.
> > > | http://oncology.medscape.com/24572.rhtml
> > > | <a href="http://oncology.medscape.com/24572.rhtml">Read it Here</a>
> > > |
> > > | PACLITAXEL BLOCKS INVASION OF KAPOSI'S SARCOMA CELLS AND INTERFERES
> >WITH
> > > | APOPTOSIS
> > > | The microtubule-stabilizing drug paclitaxel inhibits the growth of
> > > Kaposi's
> > > | sarcoma (KS) by blocking the growth, migration, and invasion of KS
> >cells
> > > | and interfering with the expression of the antiapoptotic protein
> >Bcl-2.
> > > | http://oncology.medscape.com/24605.rhtml
> > > | <a href="http://oncology.medscape.com/24605.rhtml">Read it Here</a>
> > > |
> > > | HEPARIN'S ANTI-TUMOR POTENTIAL SAID TO WARRANT CLINICAL TRIALS
> > > | The observation that heparin inhibits some kinds of tumors suggests
> >that
> > > | the anticoagulant should be subjected to clinical trials as a
> >chemotherapy
> > > | agent, according to speakers at the 13th International Symposium on
> > > | Molecular Biology of Hematopoiesis and Treatment of Leukemia and
> >Cancer.
> > > | http://oncology.medscape.com/24580.rhtml
> > > | <a href="http://oncology.medscape.com/24580.rhtml">Read it Here</a>
> > > |
> > > | THALIDOMIDE INDUCES RESPONSE IN LARGE SERIES OF MULTIPLE MYELOMA
> >PATIENTS
> > > | In the largest series of patients with refractory multiple myeloma
> >treated
> > > | with thalidomide that has been reported to date, 14% achieved a
> >complete
> > > | response or nearly complete response, with almost 50% of patients
> >still
> > > | alive after 2 years, according to Dr. Bart Barlogie of the
University
> >of
> > > | Arkansas for Medical Sciences, Little Rock.
> > > | http://oncology.medscape.com/24663.rhtml
> > > | <a href="http://oncology.medscape.com/24663.rhtml">Read it Here</a>
> > > |
> > > | 'MINI' TRANSPLANTS REPORTED EFFECTIVE FOR SOME HEMATOLOGIC
> >MALIGNANCIES
> > > | Researchers from several institutions report that 'mini' transplants
> >of
> > > | bone marrow or peripheral blood stem cells -- defined as transplants
> > > | without myeloablation and its sometimes fatal consequences -- can be
> > > | effective against a variety of hematologic malignancies, and may
even
> > > prove
> > > | superior to conventional transplants.
> > > | http://oncology.medscape.com/24583.rhtml
> > > | <a href="http://oncology.medscape.com/24583.rhtml">Read it Here</a>
> > > |
> > > | G-CSF APPEARS BENEFICIAL WITH STEM CELL TRANSPLANTATION IN CHILDREN
> > > | Granulocyte colony stimulating factor (G-CSF, filgrastim)
accelerates
> > > | neutrophil recovery in children who have received stem cell
> >transplants
> > > for
> > > | the treatment of cancer.
> > > | http://oncology.medscape.com/24732.rhtml
> > > | <a href="http://oncology.medscape.com/24732.rhtml">Read it Here</a>
> > > |
> > > | FDA ADVISORY COMMITTEE RECOMMENDS GROUND RULES FOR STEM CELL
PRODUCTS
> > > | At a meeting on Friday, the US Food and Drug Administration's (FDA)
> > > | Biological Response Modifiers Advisory Committee made several
> > > | recommendations about how the FDA should proceed in regulating the
> > > | development of stem cell-based products.
> > > | http://oncology.medscape.com/24554.rhtml
> > > | <a href="http://oncology.medscape.com/24554.rhtml">Read it Here</a>
> > > |
> > > | FDA WARNS OF SHORTAGES OF THREE DRUGS
> > > | Manufacturing problems have led to shortages or potential shortages
of
> > > | Wyeth-Ayerst's Wydase, Roche's Romazicon and Faulding's Blenoxane,
> > > | according to the US Food and Drug Administration (FDA).
> > > | http://oncology.medscape.com/24602.rhtml
> > > | <a href="http://oncology.medscape.com/24602.rhtml">Read it Here</a>
> > > |
> > > | P53-EXPRESSING ADENOVIRUS GENE THERAPY CAUSES LYMPHOMA REGRESSION IN
> >MICE
> > > | Injection of an adenovirus that expresses p53 directly into the
tumor
> > > | causes regression of established lymphomas in mice, according to
> > > scientists
> > > | in Des Moines, Iowa.
> > > | http://oncology.medscape.com/24559.rhtml
> > > | <a href="http://oncology.medscape.com/24559.rhtml">Read it Here</a>
> > > |
> > > | VACCINE BASED ON DENDRITIC CELLS APPEARS SAFE IN EARLY TRIALS OF
> >MULTIPLE
> > > | MYELOMA
> > > | A vaccine based on dendritic cells appears to be safe and may have
> >some
> > > | effect in multiple myeloma and amyloidosis, according to a report at
> >the
> > > | 13th International Symposium on Molecular Biology of Hematopoiesis
and
> > > | Treatment of Leukemia, Lymphoma and Cancer.
> > > | http://oncology.medscape.com/24792.rhtml
> > > | <a href="http://oncology.medscape.com/24792.rhtml">Read it Here</a>
> > > |
> > > | AVAX LAUNCHES NEW SKIN CANCER VACCINE IN AUSTRALIA
> > > | AVAX Technologies Inc. on Tuesday said that it is selling a
> >personalized
> > > | skin cancer vaccine in Australia, aimed at individuals whose
melanoma
> >has
> > > | already spread.
> > > | http://oncology.medscape.com/24675.rhtml
> > > | <a href="http://oncology.medscape.com/24675.rhtml">Read it Here</a>
> > > |
> > > | CPG OLIGONUCLEOTIDES ENHANCE IMMUNOGENICITY OF TUMOR VACCINE IN MICE
> > > | Researchers at the Mayo Clinic have greatly enhanced the
> >immunogenicity
> >of
> > > | protein-based melanoma vaccines in mice by repeatedly administering
> > > | synthetic oligonucleotides containing foreign
> >cytosine-phosphorothiolated
> > > | guanine (CpG) motifs.
> > > | http://oncology.medscape.com/24817.rhtml
> > > | <a href="http://oncology.medscape.com/24817.rhtml">Read it Here</a>
> > > |
> > > | CELL THERAPEUTICS' MYELODYSPLASTIC SYNDROMES DRUG RECEIVES ORPHAN
DRUG
> > > STATUS
> > > | The US Food and Drug Administration (FDA) has granted orphan drug
> >status
> > > to
> > > | Cell Therapeutics' anticancer drug treatment, Arsenic TriOxide
(ATO),
> >for
> > > | the treatment of myelodysplastic syndromes, the Seattle-based
company
> >said
> > > | on Tuesday.
> > > | http://oncology.medscape.com/24685.rhtml
> > > | <a href="http://oncology.medscape.com/24685.rhtml">Read it Here</a>
> > > |
> > > | ONYX, BAYER BEGIN CLINICAL TESTS OF POTENTIAL CANCER THERAPY
> > > | Onyx Pharmaceuticals and Bayer have begun phase I pharmacokinetic
> >clinical
> > > | testing of a ras pathway inhibitor that the companies hope will
prove
> >to
> > > be
> > > | an effective anticancer therapy, Richmond, California-based Onyx
said
> >on
> > > | Tuesday.
> > > | http://oncology.medscape.com/24670.rhtml
> > > | <a href="http://oncology.medscape.com/24670.rhtml">Read it Here</a>
> > > |
> > > | BOSTON HOSPITAL SUES ABBOTT OVER CANCER RESEARCH
> > > | A Boston research hospital countersued Abbott Laboratories Inc. on
> > > Tuesday,
> > > | claiming that the Chicago-based drug maker stole a formula for a
> >promising
> > > | cancer medicine.
> > > | http://oncology.medscape.com/24678.rhtml
> > > | <a href="http://oncology.medscape.com/24678.rhtml">Read it Here</a>
> > > |
> > > | EXPRESSION OF SOMATOSTATIN RECEPTOR REDUCES VOLUME OF PANCREATIC
> >TUMORS
> > > | Expression of the somatostatin receptor sst2, followed by treatment
> >with
> >a
> > > | cytotoxic somatostatin analog, inhibits growth of pancreatic cancers
> >in
> > > | hamsters, according to a team of French and US researchers.
> > > | http://oncology.medscape.com/24606.rhtml
> > > | <a href="http://oncology.medscape.com/24606.rhtml">Read it Here</a>
> > > |
> > > | BRCA1 PART OF A COMPLEX THAT REGULATES CHROMATIN ACCESS
> > > | Scientists have found that the breast cancer susceptibility gene
BRCA1
> > > | interacts with a protein complex that regulates access to DNA,
> >providing
> >a
> > > | major clue to how alterations in the gene might lead to breast and
> >ovarian
> > > | cancer.
> > > | http://oncology.medscape.com/24818.rhtml
> > > | <a href="http://oncology.medscape.com/24818.rhtml">Read it Here</a>
> >
> >
> >------------------------------------------------------------------------
> >This is an automatically-generated notice.  If you'd like to be removed
> >from the mailing list, please visit the Medicine-On-Line Discussion Forum
> >at <http://www.meds.com/con_faq.html>, or send an email message to:
> >majordomo@lists.meds.com
> >with the subject line blank and the body of the message containing the
> >line:
> >unsubscribe mol-cancer your-email-address
> >where the phrase your-email-address is replaced with your actual email
> >address.
> >------------------------------------------------------------------------
>
> ________________________________________________________________________
> Get Your Private, Free E-mail from MSN Hotmail at http://www.hotmail.com
>
> ------------------------------------------------------------------------
> This is an automatically-generated notice.  If you'd like to be removed
> from the mailing list, please visit the Medicine-On-Line Discussion Forum
> at <http://www.meds.com/con_faq.html>, or send an email message to:
> majordomo@lists.meds.com
> with the subject line blank and the body of the message containing the
line:
> unsubscribe mol-cancer your-email-address
> where the phrase your-email-address is replaced with your actual email
> address.
> ------------------------------------------------------------------------
>

------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------